

SPECIFIC PROPERTIES OF THE DRUG AMANTADINE AGAINST VIRUSES AND IN PARKINSON'S DISEASE**Irgashev Ibodillo Ergashevich**

Faculty of Medicine, International University of Asia, Uzbekistan

Anesthesiologist-resuscitator.

<https://doi.org/10.5281/zenodo.14743088>

Abstract. Long-term therapy of Parkinson's disease (PD) with dopaminergic agents is naturally accompanied by the appearance of symptom fluctuations and dyskinesias, and these complications are an extremely important factor that adversely affects the quality of life.

Keywords: Parkinson's disease, substantia nigra, levodopa therapy, NMDA receptors, Amantadine sulfate (PK-Merz), striocortical connections, amantadine hydrochloride.

СПЕЦИФИЧЕСКИЕ СВОЙСТВА ПРЕПАРАТА АМАНТАДИН В ОТНОШЕНИИ ВИРУСОВ И ПРИ БОЛЕЗНИ ПАРКИНСОНА

Аннотация. Длительная терапия болезни Паркинсона (БП) дофаминергическими средствами закономерно сопровождается появлением флюктуаций симптоматики и дискинезий, и эти осложнения являются крайне важным фактором, отрицательно влияющим на качество жизни.

Ключевые слова: болезнь Паркинсона, черная субстанция, терапия леводопой, NMDA-рецепторы, амантадина сульфат (ПК-Мерц), стриокортикальные связи, амантадина гидрохлорид.

In 2017, it was 200 years since the famous English physician James Parkinson described the disease that was later named after him [1]. However, despite such a significant history of studying Parkinson's disease (PD), this disease remains a serious challenge for clinical and fundamental neurology to this day. As is known, the leading motor manifestations of PD (hypokinesia, muscle rigidity, resting tremor) are caused by the death of dopamine neurons in the substantia nigra of the midbrain, degeneration of the nigrostriatal pathway and destabilization of the functional network of subcortical nuclei. A decrease in the inhibitory effect of dopamine on striatal neurons leads to a relative predominance of the activity of the cholinergic systems of the brain. Of additional importance is the excitotoxic effect of excess concentrations of glutamate, caused by the disintegration of striocortical connections due to damage to the dopaminergic mesocortical pathway. While recognizing the successes achieved, it should be emphasized that in the long term, the treatment of patients with PD is associated with a number of complex problems that are still far from being resolved.

Motor complications of long-term levodopa therapy are of significant importance in assessing the course of PD and mark the onset of the advanced stage of the disease. In the pathophysiological mechanisms of levodopa-induced dyskinesias, the key role is played by the hyperactivity of glutamatergic receptors located on the medium spiny neurons of the striatum: in dyskinesias, hyperphosphorylation of NMDA receptors is noted, which leads to an increase in synaptic efficiency and activation of the corticostriatal glutamatergic pathway. It has been shown that dyskinesias and fluctuations of symptoms significantly impede the motor activity of patients and are among the leading factors that reduce the quality of life. In its chemical structure, amantadine is a tricyclic aminoadamantane 1-aminoadamantane hydrochloride (1-adamantylamine hydrochloride). It is a white or white with a slight yellowish tint crystalline powder with a bitter taste. Amantadine also exhibits a number of other important properties:

- increased dopamine synthesis in nigral neurons;
- increased release of dopamine (and other monoamine) vesicles into the synaptic cleft and blocking the reuptake of dopamine by presynaptic terminals;
- increased sensitivity of dopaminergic receptors to the neurotransmitter;
- mild anticholinergic effect.

Amantadine is generally well tolerated in patients of all ages, although it should be used with caution after 70–75 years of age. Side effects are rare and may include swelling (usually of the shins and feet), dry mouth, mottling of the skin, sleep disturbances, episodes of agitation, and hallucinations. Today, two main forms of amantadine are known - amantadine hydrochloride and amantadine sulfate. Amantadine sulfate (PK-Merz) is characterized by a more stable concentration in the blood and the absence of any significant "peak dose" effect, so even with long-term use, it has a stable, persistent antiparkinsonian effect. Another major advantage of amantadine sulfate (PK-Merz) is the availability (in addition to the standard tablet form) of a liquid form for infusion administration. The infusion form of PK-Merz is the first and currently the only antiparkinsonian drug that can be used parenterally.

REFERENCES

1. Irgashev, I. E., & Farmonov, X. A. (2021). Specificity of resuscitation and rehabilitation procedures in patients with covid-19. *Central Asian Journal of Medical and Natural Science*, 2(1), 11-14.
2. Irgashev, I. E. (2022). New Principles of Anticoagulant Therapy in Patients with Covid-19. *Research Journal of Trauma and Disability Studies*, 1(12), 15-19.
3. Irgashev, I. E. (2023). Pathological Physiology of Heart Failure. *American Journal of Pediatric Medicine and Health Sciences* (2993-2149), 1(8), 378-383.

4. Irgashev, I. (2024). COVID-19 INFEKSIYSINI YUQTIRGAN KASALXONADAN TASHQARI PNEVMONIYA BILAN KASALLANGAN BEMORLARDA DROPERIDOL NEYROLEPTIK VOSITASINI QO'LLANILISHI VA UNING DAVO SAMARADORLIGIGA TA'SIRI. *Центральноазиатский журнал образования и инноваций*, 3(1), 12-18.
5. Irgashev, I. E. (2022). COVID-19 BILAN KASALLANGAN BEMORLARDA ANTIKAOGULYANT TERAPIYANING YANGICHA TAMOILLARI. *BARQARORLIK VA YETAKCHI TADQIQOTLAR ONLAYN ILMIY JURNALI*, 2(12), 462-466.
6. Ergashevich, I. I. (2024). GIPERTONIK KRIZ BILAN KECHAYOTGAN GIPERTONIYA KASALLIGIDA, ASORATLAR YUZ BERISHINI OLDINI OLİSHGA QARATILGAN SHOSHILINCH TERAPIYA. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 40(1), 55-61.
7. Ergashevich, I. I. (2024). SPECIFIC PROPERTIES OF LEVAMICOL OINTMENT. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 40(1), 48-53.
8. Irgashev, I. E. (2023). RESPIRATORY DISTRESS SYNDROME. *Horizon: Journal of Humanity and Artificial Intelligence*, 2 (5), 587–589.
9. Ergashevich, I. I. (2024). OTKIR KORONAR SINDROM KUZATILAYOTGAN BEMORLARDA ILK YORDAM KO'RSATISHNING USTUVOR TAMOILLARI HAMDA UNING AHAMIYATI. *TADQIQOTLAR. UZ*, 34(2), 152-159.
10. Ergashevich, I. I. (2024). GIPERTONIYA KASALLIGIDA SHOSHILINCH YORDAM KO'RSATISH. *AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI*, 3(3), 148-153.
11. Иргашев, И. Э. (2024). ПРИНЦИПЫ ПРИОРИТЕТА И ЕГО ЗНАЧЕНИЕ ОКАЗАНИЯ ПЕРВОЙ ПОМОЩИ У БОЛЬНЫХ ОСТРЫМ КОРОНАРНЫМ СИНДРОМОМ. *TADQIQOTLAR. UZ*, 34(2), 177-184.
12. Иргашев, И. Э. (2024). ДЕЙСТВИЕ ДРОПЕРИДОЛА У БОЛЬНЫХ ВНЕГОСПИТАЛЬНОЙ ПНЕВМОНИЕЙ, ИНФИЦИРОВАННЫХ КОРОНОВИРУСОМ. *TADQIQOTLAR. UZ*, 34(2), 160-168.
13. Иргашев, И. Э. (2024). ПРИНЦИПЫ ОКАЗАНИЯ ПЕРВОЙ ПОМОЩИ БОЛЬНЫМ ГИПЕРТЕНИЧЕСКИМ КРИЗОМ. *TADQIQOTLAR. UZ*, 34(2), 185-192.
14. Иргашев, И. Э. (2024). СКОРАЯ ПОМОЩЬ ПРИ ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНИ. *TADQIQOTLAR. UZ*, 34(2), 169-176

15. Усмонов, У. Р., & Иргашев, И. Э. (2020). Changes in the morphofunctional properties of thymus and spleen under the influence of mites of different origins. *Новый день в медицине*, (2), 242-244.
16. Ergashevich, I. I., Bahronovich, B. F., & Qilichevna, A. M. (2024). ASTMATIK STATUSDAN BEMORLARNI CHIQARISHNING ZAMONAVIY TAMOYILLARI. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 43(8), 36-44.
17. Ergashevich, I. I. (2024). BRONXIAL ASTMA KASALLIGINI DAVOLASHGA ZAMONAVIY YONDASHUV. *SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES*, 3(4), 266-272.
18. Иргашев, И. Э., & Ахмедова, М. К. (2024). СОВРЕМЕННЫЕ ПРИНЦИПЫ ВЫВОДА ПАЦИЕНТОВ В АСТМАТИЧЕСКОМ СТАТУСЕ. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 43(8), 28-35.
19. Saodat, A., Vohid, A., Ravshan, N., & Shamshod, A. (2020). MRI study in patients with idiopathic cokearthrosis of the hip joint. *International Journal of Psychosocial Rehabilitation*, 24(2), 410-415.
20. Axmedov, S. J. (2023). EFFECTS OF THE DRUG MILDRONATE. *Innovative Development in Educational Activities*, 2(20), 40-59.
21. Jamshidovich, A. S. (2023). ASCORBIC ACID: ITS ROLE IN IMMUNE SYSTEM, CHRONIC INFLAMMATION DISEASES AND ON THE ANTIOXIDANT EFFECTS. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, 3(11), 57-60.
22. Jamshidovich, A. S. (2023). THE ROLE OF THIOTRIAZOLINE IN THE ORGANISM. *Ta'lif innovatsiyasi va integratsiyasi*, 9(5), 152-155.
23. Jamshidovich, A. S. (2023). HEPTRAL IS USED IN LIVER DISEASES. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 35(3), 76-78.
24. Jamshidovich, A. S. (2023). EFFECT OF TIVORTIN ON CARDIOMYOCYTE CELLS AND ITS ROLE IN MYOCARDIAL INFARCTION. *Gospodarka i Innowacje.*, 42, 255-257.
25. Jamshidovich, A. S. (2024). NEUROPROTECTIVE EFFECT OF CITICOLINE. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, 4(1), 1-4.
26. Jamshidovich, A. S. (2024). THE ROLE OF TRIMETAZIDINE IN ISCHEMIC CARDIOMYOPATHY. *Journal of new century innovations*, 44(2), 3-8.

27. Jamshidovich, A. S. (2024). BCE ЭФФЕКТЫ ПРЕПАРАТА ИМУДОН. *TADQIQTOLAR*, 31(2), 39-43.
28. Jamshidovich, A. S. (2024). SPECIFIC FEATURES OF THE EFFECT OF THE HEPARIN DRUG. *TADQIQTOLAR*, 31(2), 34-38.
29. Jamshidovich, A. S. (2024). USE OF GLUCOCORTICOSTEROIDS IN PEDIATRIC PRACTICE. *TADQIQTOLAR*, 31(2), 29-33.
30. Jamshidovich, A. S. (2024). РОЛЬ ИНТЕЛЛАННОВОГО СИРОПА И ЦИАНОКОБАЛАМИНА В УЛУЧШЕНИИ ПАМЯТИ. *TADQIQTOLAR*, 31(2), 44-48.
31. Jamshidovich, A. S. (2024). TREATMENT OF POLYNEUROPATHY WITH BERLITHION. *Ta'limning zamonaviy transformatsiyasi*, 4(1), 201-209.
32. Jamshidovich, A. S. (2024). USE OF ASCORIL IN BRONCHIAL ASTHMA. *Ta'limning zamonaviy transformatsiyasi*, 4(1), 191-200.
33. Jamshidovich, A. S. (2024). THE IMPORTANCE OF THE DRUG ARTOXAN. *Ta'limning zamonaviy transformatsiyasi*, 4(1), 182-190.
34. Jamshidovich, A. S. (2024). THE ROLE OF RENGALIN IN CHRONIC BRONCHITIS. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 38(4), 116-123.
35. Jamshidovich, A. S. (2024). THE ROLE OF ALMAGEL DRUG IN GASTRIC AND DUODENAL WOUND DISEASE. *Ta'limning zamonaviy transformatsiyasi*, 4(1), 173-181.
36. Jamshidovich, A. S. (2024). THE ROLE OF CODELAK BRONCHO SYRUP IN CHILDREN'S PRACTICE. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 38(4), 109-115.
37. Jamshidovich, A. S. (2024). THE AEVIT DRUG EFFECT. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 38(4), 124-132.
38. Jamshidovich, A. S. (2024). THE IMPORTANCE OF ALCHEBA DRUG IN POST-STROKE APHASIA. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 38(4), 132-138.
39. Jamshidovich, A. S. (2024). THE ROLE OF HYALURON CHONDRO DRUG IN OSTEOARTHROSIS. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 38(4), 139-145.
40. Jamshidovich, A. S. (2024). EFFECT OF SIMETHICONE DROP IN FLATULENCE. *Лучшие интеллектуальные исследования*, 14(1), 95-101.
41. Jamshidovich, A. S. (2024). BENEFITS OF BETADINE SOLUTION. *Лучшие интеллектуальные исследования*, 14(1), 116-122.

42. Jamshidovich, A. S. (2024). EFFECT INHALED GLUCOCORTICOIDS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND BRONCHIAL ASTHMA. *TADQIQTOLAR*, 31(1), 171-180.
43. Jamshidovich, A. S. (2024). USE OF VIGANTOL IN RICKETS. *Лучшие интеллектуальные исследования*, 14(1), 102-108.
44. Jamshidovich, A. S. (2024). THE VITAPROST DRUG RESULTS. *Лучшие интеллектуальные исследования*, 14(1), 109-115.
45. Jamshidovich, A. S. (2024). THE ROLE OF BISEPTOL DRUG IN URINARY TRACT DISEASE. *Лучшие интеллектуальные исследования*, 14(1), 89-94.
46. Jamshidovich, A. S. (2024). PROPERTIES OF THE DRUG DORMIKIND. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 38(5), 88-92.
47. Jamshidovich, A. S., & Komilovich, E. B. (2024). IMMUNOMODULATORY FUNCTION OF DIBAZOL DRUG. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 38(5), 83-87.
48. Jamshidovich, A. S., & Komilovich, E. B. (2024). ADVANTAGES OF THE DRUG HEPTRAL. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 38(5), 98-101.
49. Эргашов, Б. К., & Ахмедов, Ш. Ж. (2024). ГИПЕРТОНИЧЕСКАЯ БОЛЕЗНЬ ЭТИОЛОГИЯ. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 38(6), 59-69.
50. Komilovich, E. B., & Jamshidovich, A. S. (2024). HYPERTENSION, CLASSIFICATION AND PATHOGENESIS. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 38(6), 50-58.
51. Komilovich, E. B., & Jamshidovich, A. S. (2024). YURAK ISHEMIYASI. STENOKARDIYADA SHOSHILINCH TIBBIY YORDAM. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 38(6), 12-20.
52. Komilovich, E. B., & Jamshidovich, A. S. (2024). HYPERTENSION ETIOLOGY. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 38(6), 32-41.
53. Komilovich, E. B., & Jamshidovich, A. S. (2024). CARDIAC ISCHEMIA. ANGINA NURSING DIAGNOSIS AND CARE. *Journal of new century innovations*, 46(1), 44-52.
54. Jamshidovich, A. S. (2024). IMPORTANT INDICATIONS OF THE DRUG WOBENZYM. *Journal of new century innovations*, 46(1), 29-32.

55. Jamshidovich, A. S. (2024). THE RESULTS OF THE EFFECT OF THE DRUG VALIDOL. *Journal of new century innovations*, 46(1), 19-23.
56. Jamshidovich, A. S. (2024). VIFERON USE IN CHILDREN. *Journal of new century innovations*, 46(1), 24-28.
57. Jamshidovich, A. S. (2024). USE OF DUSPATALIN (МЕВЕВЕРИН HYDROCHLORIDE) IN GASTROINTESTINAL DISEASES. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 38(5), 93-97.
58. Jamshidovich, A. S. (2024). ЭФФЕКТЫ СИРОПА ДЕПАКИНА (ВАЛЬПРОЕВАЯ КИСЛОТА). *Ta'lim innovatsiyasi va integratsiyasi*, 14(2), 148-152.
59. Jamshidovich, A. S., & Komilovich, E. B. (2024). THE IMPORTANCE OF THE DRUG ALLOCHOL FOR CHRONIC CHOLECYSTITIS. *Ta'lim innovatsiyasi va integratsiyasi*, 14(2), 133-137.
60. Jamshidovich, A. S., & Komilovich, E. B. (2024). ВАЖНЫЕ СВОЙСТВА ПРЕПАРАТА ДЕ-НОЛ (субцитрат висмута). *Ta'lim innovatsiyasi va integratsiyasi*, 14(2), 143-147.
61. Jamshidovich, A. S., & Komilovich, E. B. (2024). SPECIAL FEATURES OF BUDECTON DRUG. *Ta'lim innovatsiyasi va integratsiyasi*, 14(2), 138-142.
62. Jamshidovich, A. S. (2024). ЭФФЕКТИВНОЕ ВОЗДЕЙСТВИЕ ПРЕПАРАТА КЕЙВЕР. *Ta'lim innovatsiyasi va integratsiyasi*, 15(3), 137-143.
63. Jamshidovich, A. S. (2024). USEFUL PROPERTIES OF THE DRUG YODOFOL. *Ta'lim innovatsiyasi va integratsiyasi*, 15(3), 144-149.
64. Jamshidovich, A. S. (2024). FITOTERAPIYANING AKUSHER-GINEKOLOGIYADA AHAMIYATI. *Лучшие интеллектуальные исследования*, 15(2), 121-125.
65. Jamshidovich, A. S. (2024). THE IMPORTANCE OF THE DRUG DOPROKIN. *Лучшие интеллектуальные исследования*, 15(2), 109-114.
66. Jamshidovich, A. S. (2024). THE EFFECT OF DOSTINEX ON THE BODY. *Лучшие интеллектуальные исследования*, 15(2), 115-120.
67. Jamshidovich, A. S. (2024). РЕЗУЛЬТАТЫ ЭФФЕКТИВНОГО ДЕЙСТВИЯ ПРЕПАРАТА КАНЕФРОН. *Лучшие интеллектуальные исследования*, 15(2), 138-143.
68. Jamshidovich, A. S. (2024). СОВРЕМЕННЫЕ ЭФФЕКТЫ ПРЕПАРАТА ИНДОЛ. *Лучшие интеллектуальные исследования*, 15(2), 126-131.
69. Jamshidovich, A. S. (2024). EFFECT OF ISMIZHEN DRUG ON BODY IMMUNITY. *Лучшие интеллектуальные исследования*, 15(2), 132-137.

70. Jamshidovich, A. S. (2024). POSITIVE EFFECTS OF THE DRUG CARCIL. *Ta'lim innovatsiyasi va integratsiyasi*, 15(3), 127-131.
71. Jamshidovich, A. S. (2024). РЕЗУЛЬТАТЫ ЭФФЕКТИВНОГО ДЕЙСТВИЯ КАВИНТОНА. *Ta'lim innovatsiyasi va integratsiyasi*, 15(3), 132-136.
72. Jamshidovich, A. S. (2024). Современный Эффект Спрея Мометазон. *Research Journal of Trauma and Disability Studies*, 3(3), 62-65.
73. Jamshidovich, A. S. (2024). THE ROLE OF "SIMONTE PLUS" DRUG IN THE MODERN TREATMENT OF BRONCHIAL ASTHMA. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, 4(5), 66-70.
74. Jamshidovich, A. S. (2024). FEATURES OF THE BIOMECHANISM OF THE DRUG LEVOMYCETIN (CHLORAMPHENICOL). *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, 4(9), 298-301.
75. Jamshidovich, A. S. (2024). THE MOST IMPORTANT INDICATORS OF OMEGA 3 SUBSTANCE IN THE METABOLISM OF THE HUMAN BODY. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, 4(10), 113-117.
76. Komilovich, E. B., & Khalimovich, M. N. (2024). CARDIAC ISCHEMIA. ANGINA CLINICAL FORMS AND DIAGNOSIS. *Journal of new century innovations*, 46(1), 70-78.
77. Komilovich, E. B. (2024). CORONARY HEART DISEASE. ANGINA EMERGENCY CARE. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 38(7), 235-242.
78. Komilovich, E. B. (2024). YURAK ISHEMIK KASALLIGI. STENOKARDIYANI DAVOLASHNING ZAMONAVIY TAMOYILLARI. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 38(6), 3-11.
79. Komilovich, E. B., & Khalimovich, M. N. (2024). DEPENDENCIES IN THE CLINIC AND DIAGNOSIS OF CORONARY HEART DISEASE AND ARTERIAL HYPERTENSION. *Journal of new century innovations*, 46(1), 61-69.
80. Komilovich, E. B., & Xalimovich, M. N. (2024). YURAK ISHEMIYASIDA HAMSHIRALIK DIAGNOSTIKASI VA PARVARISHI. *Journal of new century innovations*, 46(1), 79-85.
81. Komilovich, E. B., & Khalimovich, M. N. (2024). NURSING CARE FOR CORONARY ARTERY DISEASE, ANGINA PECTORIS. *Journal of new century innovations*, 46(1), 86-94.

82. Jamshidovich, A. S. (2024). THE MOST IMPORTANT BENEFITS OF GINGER FOR THE HUMAN BODY'S IMMUNITY. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, 4(11), 269-273.
83. Axmedov, S. (2024). THE SPECIFIC EFFECT OF THE DRUG "BAKLASAN" IN CEREBROVASCULAR DISEASES AND ITS PRACTICAL SIGNIFICANCE TODAY. *Modern Science and Research*, 3(12), 485-492.
84. Axmedov, S. (2025). ВАЖНЫЕ СВОЙСТВА ПРЕПАРАТА ЭСКУЗАН ПРИ СОСУДИСТЫХ ЗАБОЛЕВАНИЯХ. *Modern Science and Research*, 4(1), 380-387.
85. Xusenovich, M. S., & Turapjanovna, Z. M. (2024). SEMIZLIKNING TURLI FENOTIPLARDA KARDIOMETABOLIK XAVF OMILLARINI TAQQOSLASH. *SO'NGI ILMIY TADQIQOTLAR NAZARIYASI*, 7(4), 112-116.
86. Husenovich, M. S., & Turabdjanova, Z. M. (2024). STUDY OF DIURNAL PROFILE OF ARTERIAL HYPERTENSION IN DIFFERENT PHENOTYPE OBESITY. *образование наука и инновационные идеи в мире*, 43(1), 129-131.
87. Xusenovich, M. S. (2024, September). SEMIZLIKNI TURLI FENOTIPLARIDA YURAK QON-TOMIR KASALLIKLARINI KELIB CHIQISH XAVFI PROGNOZI. In *INTERNATIONAL SCIENTIFIC RESEARCH CONFERENCE* (Vol. 3, No. 26, pp. 15-18).
88. Xusenovich, M. S. (2024). O 'ZBEKISTONDA RESPUBLIKASIDA YURAK-QON TOMIR KASALLIKLARI TARQALISHI VA HOZIRGI KUNDAGI KO'RILAYOTGAN CHORA TADBIRLAR. *AMERICAN JOURNAL OF SOCIAL SCIENCE*, 2(3), 79-82.
89. Xusenovich, M. S., & Allayarovich, A. A. (2024). O 'ZBEKISTONDA YURAK-QON TOMIR KASALLIKLARI TARQALISHI VA HOZIRGI KUNDAGI TENDENSIYASI. *MODELS AND METHODS FOR INCREASING THE EFFICIENCY OF INNOVATIVE RESEARCH*, 4(38), 54-57.
90. Ravshanovna, X. L. (2021, June). MINIMALLY INVASIVE METHODS OF TREATMENT OF DENTAL CARIES IN ADULTS. In " *ONLINE-CONFERENCES" PLATFORM* (pp. 118-119).